Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HTL0018318 in Healthy Japanese and Caucasian Subjects
NCT03198624Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTL0018318 in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) (6 arms), sponsored by Nxera Pharma. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 1 more. Started May 2017; status: completed.
02
Drugs
HTL0018318
03
Conditions
Alzheimer's disease (AD)dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT03198624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198624.